American Oriental Bioengineering, Inc. (AOBI)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2012 | 44.35 Million USD | -55.53% |
| 2011 | 99.75 Million USD | -36.77% |
| 2010 | 157.75 Million USD | -5.41% |
| 2009 | 166.78 Million USD | -3.93% |
| 2008 | 173.61 Million USD | 56.24% |
| 2007 | 111.11 Million USD | 54.62% |
| 2006 | 71.86 Million USD | 104.59% |
| 2005 | 35.12 Million USD | 69.69% |
| 2004 | 20.69 Million USD | 55.05% |
| 2003 | 13.34 Million USD | 112.18% |
| 2002 | 6.29 Million USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 12.73 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2013 Q1 | 4.5 Million USD | -83.35% |
| 2013 Q3 | 3.1 Million USD | -37.67% |
| 2013 Q2 | 4.98 Million USD | 10.78% |
| 2012 Q1 | 7.68 Million USD | -67.49% |
| 2012 FY | 44.35 Million USD | -55.53% |
| 2012 Q4 | 27.02 Million USD | 318.62% |
| 2012 Q3 | 6.45 Million USD | 102.25% |
| 2012 Q2 | 3.19 Million USD | -58.44% |
| 2011 Q4 | 23.62 Million USD | -6.26% |
| 2011 FY | 99.75 Million USD | -36.77% |
| 2011 Q3 | 25.2 Million USD | -2.48% |
| 2011 Q2 | 25.84 Million USD | 3.07% |
| 2011 Q1 | 25.07 Million USD | -40.86% |
| 2010 Q2 | 39.84 Million USD | 41.09% |
| 2010 Q3 | 47.28 Million USD | 18.68% |
| 2010 Q4 | 42.39 Million USD | -10.33% |
| 2010 Q1 | 28.23 Million USD | -46.33% |
| 2010 FY | 157.75 Million USD | -5.41% |
| 2009 Q2 | 41.62 Million USD | 46.49% |
| 2009 FY | 166.78 Million USD | -3.93% |
| 2009 Q4 | 52.6 Million USD | 19.21% |
| 2009 Q1 | 28.41 Million USD | -52.68% |
| 2009 Q3 | 44.13 Million USD | 6.02% |
| 2008 FY | 173.61 Million USD | 56.24% |
| 2008 Q1 | 26.29 Million USD | -32.77% |
| 2008 Q4 | 60.04 Million USD | 27.24% |
| 2008 Q3 | 47.19 Million USD | 17.74% |
| 2008 Q2 | 40.08 Million USD | 52.45% |
| 2007 Q3 | 30.68 Million USD | 29.44% |
| 2007 Q4 | 39.1 Million USD | 27.46% |
| 2007 Q1 | 17.7 Million USD | -31.42% |
| 2007 FY | 111.11 Million USD | 54.62% |
| 2007 Q2 | 23.7 Million USD | 33.88% |
| 2006 Q4 | 25.81 Million USD | 42.64% |
| 2006 FY | 71.86 Million USD | 104.59% |
| 2006 Q3 | 18.09 Million USD | 19.99% |
| 2006 Q2 | 15.08 Million USD | 19.92% |
| 2006 Q1 | 12.57 Million USD | -2.43% |
| 2005 Q4 | 12.89 Million USD | 51.75% |
| 2005 Q1 | 6.02 Million USD | -19.82% |
| 2005 Q2 | 7.71 Million USD | 28.02% |
| 2005 Q3 | 8.49 Million USD | 10.13% |
| 2005 FY | 35.12 Million USD | 69.69% |
| 2004 Q3 | 4.93 Million USD | 18.63% |
| 2004 Q2 | 4.16 Million USD | 1.82% |
| 2004 Q1 | 4.08 Million USD | 0.72% |
| 2004 FY | 20.69 Million USD | 55.05% |
| 2004 Q4 | 7.51 Million USD | 52.23% |
| 2003 Q4 | 4.05 Million USD | 16.92% |
| 2003 Q1 | 2.86 Million USD | 84.75% |
| 2003 Q2 | 2.95 Million USD | 3.12% |
| 2003 Q3 | 3.47 Million USD | 17.41% |
| 2003 FY | 13.34 Million USD | 112.18% |
| 2002 Q3 | 1.84 Million USD | 30.42% |
| 2002 Q1 | - USD | 0.0% |
| 2002 FY | 6.29 Million USD | 0.0% |
| 2002 Q4 | 1.55 Million USD | -15.85% |
| 2002 Q2 | 1.41 Million USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 FY | - USD | -100.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | - USD | -100.0% |
| 2000 FY | 12.73 Thousand USD | 0.0% |
| 2000 Q1 | 3689.00 USD | 0.0% |
| 2000 Q2 | 6914.00 USD | 87.42% |
| 2000 Q3 | 70.00 USD | -98.99% |
| 2000 Q4 | 2059.00 USD | 2841.43% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 1818788.561% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -278.932% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 13983.206% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 62.758% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 271.943% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 92016.148% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 35800.167% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -195.738% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -1429874.662% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -352.908% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -67386.937% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 129991.11% |
| Mesoblast Limited | -35.16 Million USD | 226.131% |
| Marizyme, Inc. | 457.7 Thousand USD | -9591.418% |
| Genus plc | 178.7 Million USD | 75.177% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 79.847% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -71185.016% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -10714.627% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 403352.855% |
| ContraFect Corporation | -154 Thousand USD | 28903.775% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 88815.628% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -57686.915% |
| IMV Inc. | -962.29 Thousand USD | 4709.571% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 11547.148% |
| MultiCell Technologies, Inc. | 49.32 USD | -89938695.62% |
| ONE Bio Corp. | 20.12 Million USD | -120.407% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -10.165% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -90611.276% |
| Q BioMed Inc. | -8988.00 USD | 493622.63% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -56.991% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 287689.562% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 3985.678% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -63268.306% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 895855.533% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -31471.398% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 45588.196% |
| GB Sciences, Inc. | -624.00 USD | 7108724.038% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 51662.066% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.413% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 21325972.115% |
| Enzolytics Inc. | 30.7 Thousand USD | -144350.352% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -9094.606% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 95.998% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 8721.371% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -7084.801% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 89.169% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 500978.659% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 53002.019% |
| Kadimastem Ltd | -630.13 Thousand USD | 7139.381% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -4389.744% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -361.532% |
| BioStem Technologies, Inc. | 15.42 Million USD | -187.574% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 374901.977% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -25023.365% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -25023.365% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -3168.47% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 153057.979% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -9756.35% |
| SYBLEU INC | 11.69 Thousand USD | -379156.276% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -862.626% |
| Bioxytran, Inc. | -8285.00 USD | 535499.083% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 11992.175% |
| Neutra Corp. | 14.33 Thousand USD | -309337.14% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 54194.895% |
| PureTech Health plc | -1.6 Million USD | 2867.175% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 4530.306% |
| IXICO plc | 3.27 Million USD | -1256.508% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 6491.616% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 2576.707% |
| CSL Limited | 7.7 Billion USD | 99.424% |
| Cellectis S.A. | 18 Thousand USD | -246332.3% |